Login
$ANIP
$70.84 -$0.60 (0.84%) Live

$ANIP 8-K SEC Filings

Filed On Filing
16 Nov 2026 8-K: Regulation FD Disclosure

Date of Report (Date of Earliest Event Reported): November 16, 2026

05 Nov 2026 8-K: Entry into a Material Definitive Agreement; Creation of a Direct Financial Obligation +1 more

CREDIT AGREEMENT, dated as of November 4, 2026, by and among ANI PHARMACEUTICALS, Inc., a Delaware corporation (the “Lead Borrower”), the Additional Subsidiary Borrowers (as hereinafter defined), the Guarantors (as hereinafter defined), ...

05 Nov 2026 8-K: Results of Operations and Financial Condition; Regulation FD Disclosure

PRINCETON, N.J., November 5, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (ANI or the Company) today announced financial results and business highlights for the third quarter ended September 30, 2026.

24 Aug 2026 8-K: Departure/Election of Directors or Officers; Compensation

– Appointment strengthens board as ANI accelerates transformation into a leading Rare Disease Company –

07 Aug 2026 8-K: Results of Operations and Financial Condition; Regulation FD Disclosure

PRINCETON, N.J., August 7, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (ANI or the Company) today announced financial results and business highlights for the second quarter ended June 30, 2026.

21 May 2026 8-K: Departure/Election of Directors or Officers; Compensation; Submission of Matters to a Vote of Security Holders

The purpose of the ANI Pharmaceuticals, Inc. Amended and Restated 2022 Stock Incentive Plan (this “Plan”) is to advance the interests of ANI Pharmaceuticals, Inc. (the “Company”) and its stockholders by enabling the Company and its Subsi...

13 May 2026 8-K: Regulation FD Disclosure

© 2026 ANI Pharmaceuticals, Inc. 1 Corporate Presentation May 2026

08 May 2026 8-K: Results of Operations and Financial Condition

PRINCETON, N.J., May 8, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (ANI or the Company) today announced financial results and business highlights for the first quarter ended March 31, 2026.

07 Apr 2026 8-K: Changes in Registrant's Certifying Accountant

We have read Item 4.01 of Form 8-K dated April 7, 2026 of ANI Pharmaceuticals, Inc. and are in agreement with the statements contained therein as it regards our firm. We have no basis to agree or disagree with other statements of the reg...

03 Mar 2026 8-K: Regulation FD Disclosure

© 2026 ANI Pharmaceuticals, Inc. 1 Corporate Presentation March 2026

27 Feb 2026 8-K: Results of Operations and Financial Condition

ANI Pharmaceuticals Reports Record Fourth Quarter and Full Year 2025 Financial Results and Reaffirms 2026 Financial Guidance

12 Jan 2026 8-K: Results of Operations and Financial Condition; Regulation FD Disclosure

© 2026 ANI Pharmaceuticals, Inc. 1 Corporate Presentation January 2026

01 Dec 2025 8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure

Patrick D. Walsh steps down as Chairman and will complete his current term as Board member

10 Nov 2025 8-K: Results of Operations and Financial Condition; Regulation FD Disclosure

© 2025 ANI Pharmaceuticals, Inc. 1 Corporate Presentation November 2025

07 Nov 2025 8-K: Results of Operations and Financial Condition

PRINCETON, N.J., November 7, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (ANI or the Company) today announced financial results and business highlights for the third quarter ended September 30, 2025.

26 Sep 2025 8-K: Unregistered Sales of Equity Securities; Material Modification to Rights of Security Holders
08 Sep 2025 8-K: Results of Operations and Financial Condition; Regulation FD Disclosure

© 2025 ANI Pharmaceuticals, Inc. 1 Corporate Presentation September 2025

08 Aug 2025 8-K: Results of Operations and Financial Condition

BAUDETTE, Minn., August 8, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (ANI or the Company) today announced financial results and business highlights for the second quarter ended June 30, 2025.

29 Jul 2025 8-K: Other Events

On March 4, 2024, ANI Pharmaceuticals, Inc. (the “Company”) commenced a civil action against CG Oncology, Inc. f/k/a Cold Genesys, Inc. (“CG Oncology”) in the Superior Court of the State of Delaware. The Company’s complaint alleges that,...

23 Jul 2025 8-K: Other Events

Disclaimers 2 Forward-Looking Statements This presentation contains forward-looking statements within the meaning of Section 27A of the Act, and Section 21E of the Securities Exchange Act of 1934, as amended. Any statements about our exp...

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support